FDA Approves Ojjaara for Myelofibrosis; EMA Gra...

Molluscum contagiosum, which affects around 6 million individuals in the United States, predominantly children, is a highly contagious viral skin disease characterized by unique, raised pinkish lesions that are irritating and often painful. These lumps can also cause inflammation and raise the risk of infection in ...

The desire for natural beauty that can improve one's health and appearance without having any negative side effects is rising as consumers are becoming more cautious about the food they eat and the products they introduce into their bodies. Nutricosmetics are one such category of product that fit with the modern cu...

FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to decrease blood sugar together with diet and exercise in children 10 years and older w...

GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...